Document is current
Any future updates will be listed below
-
Authors
Hudson, Myla https://orcid.org/0009-0009-5737-3629
Newman, Robert H.
Rorie, Checo J. https://orcid.org/0000-0002-7130-6790
Holloman, Bryan L.
Kaufman, Howard L. https://orcid.org/0000-0003-1131-004X
Rabkin, Samuel D. https://orcid.org/0000-0003-2344-2795
Graves, Joseph Jr. https://orcid.org/0000-0001-8446-1709
Saha, Dipongkor https://orcid.org/0000-0002-9923-5533
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA160762, R01 CA160762)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (1R35GM153737, 1R35GM153737)
- License Information
-
More Information
Article History
Received: 30 March 2025
Revised: 29 August 2025
Accepted: 3 September 2025
First Online: 16 September 2025
Competing interests
: SDR is a co-inventor on patents relating to oncolytic herpes simplex viruses, owned, and managed by Georgetown University and Massachusetts General Hospital, which have received royalties from Amgen and Acti\Vec Inc., and acted as a consultant and received honoraria from Replimune, Cellinta, and Greenfire Bio, and honoraria and equity from EG 427. HLK is an employee of Ankyra Therapeutics and has received honoraria for participating on advisory boards for Castle Biosciences, Midatech Pharma, Marengo Therapeutics, and Virogin. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
